Advanced in Neuroendocrine Tumor

Dr. Tony Philip

Hematology Oncology | Oncology | Hematology
North Shore Health System Medical Faculty Group Practice Inc
27005 76th Ave, 
New Hyde Park, NY 
 (478.6 mi)
Offers Telehealth
Advanced in Neuroendocrine Tumor
North Shore Health System Medical Faculty Group Practice Inc
27005 76th Ave, 
New Hyde Park, NY 
 (478.6 mi)
OverviewInsuranceLocationsClinical Research

Overview

Tony Philip is a Hematologist Oncology specialist and an Oncologist in New Hyde Park, New York. Dr. Philip and is rated as an Advanced provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Rhabdomyosarcoma Embryonal, and Colorectal Cancer.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Northwell Hospital Glen Cove
Long Island Jewish Medical Center
North Shore University Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

NORTH SHORE HEALTH SYSTEM MEDICAL FACULTY GROUP PRACTICE INC
27005 76th Ave, New Hyde Park, NY 11040

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: February 25, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: February 14, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Multicenter Study With an Open-label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor Peposertib (M3814) in Combination With Capecitabine and RT in Participants With Locally Advanced Rectal Cancer
A Multicenter Study With an Open-label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor Peposertib (M3814) in Combination With Capecitabine and RT in Participants With Locally Advanced Rectal Cancer
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
Feasibility of Assessing Drug Response to Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Patients Undergoing Surgery.
Feasibility of Assessing Drug Response to Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Patients Undergoing Surgery.
Enrollment Status: Completed
Publish Date: September 24, 2021
Intervention Type: Drug, Device
Study Drug: Multiple drug microinjection
Study Phase: Phase 1
View 8 Less Clinical Trials

7 Total Publications

"I have a doctor that handles all the other stuff." Perceptions of older adults with cancer about discussing aging-related conditions with their oncologists.
"I have a doctor that handles all the other stuff." Perceptions of older adults with cancer about discussing aging-related conditions with their oncologists.
Journal: Journal of geriatric oncology
Published: July 28, 2023
Similar Doctors
Edward M. Wolin
Elite in Neuroendocrine Tumor
Dr. Edward M. Wolin
Oncology | Hematology Oncology
Elite in Neuroendocrine Tumor
Dr. Edward M. Wolin
Oncology | Hematology Oncology

Icahn School Of Medicine At Mount Sinai

10 E 102nd St, Tisch Dept Of Mount Sinai, 
New York, NY 
 (13.1 mi)
212-844-8288
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edward Wolin is an Oncologist and a Hematologist Oncology provider in New York, New York. Dr. Wolin and is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Liver Embolization, and Endoscopy.

Diane L. Reidy-Lagunes
Elite in Neuroendocrine Tumor
Dr. Diane L. Reidy-Lagunes
Hematology Oncology | Hematology | Oncology
Elite in Neuroendocrine Tumor
Dr. Diane L. Reidy-Lagunes
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (13.0 mi)
212-639-2000
Languages Spoken:
English
Offers Telehealth

Diane Reidy-Lagunes is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Reidy-Lagunes and is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, Liver Embolization, and Pancreaticoduodenectomy.

Nitya P. Raj
Elite in Neuroendocrine Tumor
Dr. Nitya P. Raj
Hematology Oncology | Oncology
Elite in Neuroendocrine Tumor
Dr. Nitya P. Raj
Hematology Oncology | Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (13.0 mi)
212-639-2000
Experience:
15+ years
Languages Spoken:
English
Offers Telehealth

Nitya Raj is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Raj has been practicing medicine for over 15 years and is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Adrenocortical Carcinoma, Liver Embolization, and Endoscopy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile